NCT06129981

Brief Summary

We now have many pharmacological and psychotherapeutic treatments for patients suffering from Post Traumatic Stress Disorder (PTSD), including cognitive and behavioral therapy (CBT) by reactivation of traumatic memories. Despite remarkable initial efficacy, only one-third of patients treated with CBT show lasting clinical improvement. On the other hand, the associated drop-out rates vary from 17% to 33%, which may be linked to the difficulty of the task, which implies reactivating the traumatic memory (Bradley et al. 2005). Alternative treatments for PTSD include blocking chemo-facilitated memory reconsolidation with a beta-blocker, propranolol. Briefly, reconsolidation theory posits that a recalled memory becomes unstable again before consolidating again into long-term memory, hence the term "reconsolidation". During this phase of transitory plasticity, the memory can be modulated, in particular its emotional charge. The use of propranolol has shown its benefit during this phase in patients suffering from PTSD (Brunet et al, 2018). However, the use of this facilitated chemo therapy is limited to patients with no contraindication to taking beta-blockers. In this context, a non-medicinal alternative to attenuate the emotional strength of the memory has a therapeutic interest. One of the ways in which our emotional experience can be modulated is through the perception of our emotional behavior. According to the theory of self-perception (Bem, 1972) individuals become aware or conscious of their attitudes, emotions and other internal states in part by inferring them from the observation of their own behaviors. Thus when individuals produce sounds or facial expressions typical of specific emotions such as joy, sadness or anger, they will tend to experience an emotional state congruent with their vocal or facial production (Hatfield and Hsee, 1995). Work on the influence of voice perception, in particular, is experiencing a new boom due to technical developments in the fields of acoustic signal processing. In particular, Dr. Aucouturier's team has created a software device to directly modify the emotional tone of speech formulated orally. For example, for "happy" manipulation, the pitch of the voice is changed with a pitch shifting algorithm to make it more positive, the dynamic range of the voice is increased with a compression algorithm to make it more confident, and its spectral content is modified with a high-pass filter to make it brighter. The results of this work (Aucouturier et al. 2016; Rachman et al. 2018; Goupil et al., 2021) showed an emotional vocal feedback effect: the subjective evaluation that participants make of their emotional state after modification by the device goes in the direction of the emotion created by the platform, even though the participants are typically unaware of the operated modulation. The non-detection of the transformation being a necessary condition for observing the effect of VF on the emotional state of the participant. The rationale of this study is to test the use of a real-time vocal transformation paradigm during exposure therapy by reactivation of traumatic memory in imagination in patients. During this therapy, the patient is asked to read aloud the very detailed script of the traumatic event. We want to test whether manipulating the emotional tone of the patient's voice online, when reading, can have a facilitating impact on the process of reducing the emotional charge associated with the traumatic script. In order to justify the use of the audio headphones as well as the microphone, and to ensure us of the non-detectability of the transformation operated on the voice, we will explain to our patients that this device (hearing his voice in a headphone during the session of re-exposure to a memory) aims to increase immersion. Our main objective will be to assess the acceptability of this augmented form of psychotherapy, and our secondary objectives will be to assess its technical feasibility and provide initial elements to assess its effectiveness. The results will be compared with data from the literature on the usual treatment (imaginary exposure therapy, with or without propranolol according to the indications).

Trial Health

45
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
4mo left

Started Nov 2023

Typical duration for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress90%
Nov 2023Aug 2026

First Submitted

Initial submission to the registry

August 21, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

November 13, 2023

Completed
17 days until next milestone

Study Start

First participant enrolled

November 30, 2023

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2026

Last Updated

May 22, 2026

Status Verified

May 1, 2026

Enrollment Period

2.8 years

First QC Date

August 21, 2023

Last Update Submit

May 19, 2026

Conditions

Keywords

Post-traumatic stress disorderAugmented TherapyVoice TransformationsAlgorithms

Outcome Measures

Primary Outcomes (1)

  • assess whether the use of the vocal feedback (VF) device during imaginative exposure psychotherapy is acceptable for patients with PTSD.

    Patient compliance with VF-enhanced exposure psychotherapy evaluated by the drop-out rate, including loss of sight of patients who do not show up for the scheduled session and no longer respond to the solicitations of the clinical team, and the discontinuation of patients who express the wish to withdraw from the study.

    For the duration of the study for each patient; i.e. 12 months

Secondary Outcomes (10)

  • Assess other aspects of the acceptability of the VF system: assess the evolution of patients' motivation

    Throughout the duration of therapy for the patient + the initial V0 visit, i.e. an average of 7 weeks, or even a few weeks more depending on the number of sessions required to sufficiently reduce PTSD symptoms (PCL-5 < 33).

  • Assess other aspects of the acceptability of the VF system: - evaluate the evolution of patients' emotional feelings

    Throughout the duration of therapy for the patient + the initial V0 visit, i.e. an average of 7 weeks, or even a few weeks more depending on the number of sessions needed to sufficiently reduce PTSD symptoms (PCL-5 < 33).

  • Assess the feasibility of the VF system: assess the ability of the VF device to acoustically modify the patient's voice in the direction of an attenuation of the negative emotional tone

    For the entire duration of VF-enhanced exposure therapy, i.e. an average of 5 weeks per patient, or even a few weeks more depending on the number of sessions required to sufficiently reduce PTSD symptoms (PCL-5 < 33)

  • Assess the feasibility of the VF system: assess the rate of detectability by the patient of the vocal transformation applied to his voice during VF-enhanced psychotherapy

    For the entire duration of VF-enhanced exposure therapy, i.e. an average of 5 weeks per patient, or even a few weeks more depending on the number of sessions needed to sufficiently reduce PTSD symptoms (PCL-5 < 33).

  • provide initial elements for evaluating the effectiveness of the device on the reduction of post-traumatic symptoms: assess the evolution of PTSD symptoms after S6 (or Sn, n being defined by the PCL-5<33 criterion)

    Throughout the duration of the study for each patient, i.e. 12 months.

  • +5 more secondary outcomes

Study Arms (1)

Imaginary exposure therapy augmented by vocal feedback in patients fulfilling the criteria for PTSD

EXPERIMENTAL
Behavioral: Imaginary exposure therapy augmented by vocal feedback

Interventions

The procedure specific to the study * adding inclusion procedures (explanation of the study, verification of inclusion and non-inclusion criteria, signature of informed consent) * including, in the usual initial V0 visit, psychometric measures specific to the study (RSDI, CGI, PMI, GEW) * including a single usual psychotherapy session (i.e. not augmented) S1, during which the psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study are used * adding the VF device and using psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study during psychotherapy sessions S2 to Sn (minimum S6) * adding, during the last usual end-of-treatment visit, psychometric measures specific to the study (CGI) * adding psychometric measures specific to the study during the usual follow-up visit at 3 months * adding a follow-up visit at 12 months (CGI, PCL-5), either by telephone or on-site.

Imaginary exposure therapy augmented by vocal feedback in patients fulfilling the criteria for PTSD

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female over the age of 18
  • Meeting DSM-5 criteria for Post-Traumatic Stress Disorder
  • Presenting a PCL-5 strictly greater than 32 (PCL-5, Weathers et al., 2013)
  • Giving consent by signing the consent form after clear and honest information about the study.
  • Being able to understand, speak and read French

You may not qualify if:

  • Deaf, dumb or hearing aid patient
  • Minors or adults under guardianship or curatorship, under judicial protection, persons deprived of liberty
  • Suffering from a bipolar or psychotic disorder
  • Having suffered a head trauma for less than a year or having clinical symptoms and carrying neurological sequelae
  • Presenting a proven severe suicidal risk (Mini-International Neuropsychiatric Interview-Suicidality module, MINI-S and medical examination)
  • Suffering from a substance use disorder (MINI-DSM5)
  • Being treated for less than 2 months with antidepressants
  • Not being affiliated to a social security scheme
  • Pregnant or breastfeeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental Disorders
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 21, 2023

First Posted

November 13, 2023

Study Start

November 30, 2023

Primary Completion (Estimated)

August 31, 2026

Study Completion (Estimated)

August 31, 2026

Last Updated

May 22, 2026

Record last verified: 2026-05